KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.

Mei ZhouPrabhakar Pitta VenkataSuryavathi ViswanadhapalliBridgitte PalaciosSalvador AlejoYihong ChenYi HeUday P PratapJunhao LiuYi ZouZhao LaiTakayoshi SuzukiAndrew J BrennerRajeshwar R TekmalRatna K VadlamudiGangadhara R Sareddy

Published in: Breast cancer research and treatment (2020)

Our results establish that KDM1A inhibition mitigates CSCs functions via inhibition of STAT3 and EMT signaling, and KDM1A inhibitor NCD38 may represent a novel class of drug for treating TNBC.

Keyphrases

epithelial mesenchymal transition
cell proliferation
emergency department
cancer stem cells
radiation therapy
radiation induced
signaling pathway
drug induced
adverse drug
electronic health record